<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330079</url>
  </required_header>
  <id_info>
    <org_study_id>ENTRY trial</org_study_id>
    <nct_id>NCT04330079</nct_id>
  </id_info>
  <brief_title>Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease</brief_title>
  <official_title>Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease (ENTRY Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of dapagliflozin therapy on
      myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients
      with stable CAD.

      Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in
      prediabetic patients with stable CAD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 21, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in global myocardial perfusion reserve (MPR) index</measure>
    <time_frame>6months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in regional myocardial perfusion reserve (MPR) index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute changes in global MPR index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute changes in regional MPR index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure(systolic, diastolic both )</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin 10mg once daily for 6 months.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>lifestyle modification (diet and exercise) for 6 months</description>
    <arm_group_label>Lifestyle modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women at least 18 years of age

          2. Prediabetes by ADA criteria (fasting glucose 100-125mg/dl, or HbA1C 5.7-6.4%)

          3. Stable coronary artery disease

          4. Global myocardial perfusion reserve (MPR) index &lt; 2.0

          5. The patient or guardian agrees to the study protocol and the schedule of clinical and
             dynamic SPECT follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          1. Contraindications to dapagliflozin

          2. Significant renal disease manifested by eGFR&lt;30 ml/min/1.73mÂ²

          3. Unstable or rapidly progressing renal disease

          4. Acute coronary syndrome, or any other major cardiovascular events within the previous
             6 months

          5. Stent placement, or coronary artery bypass graft surgery within the previous 6 months

          6. Planned revascularization within 6 months

          7. Significant disease (diameter stenosis &gt;70% by coronary CT angiography) in major
             epicardial coronary arteries

          8. Heart failure requiring loop diuretics

          9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

         10. Contraindication to adenosine stress test

         11. Current treatment for the active cancer

         12. Women of child bearing potential who are not willing to use a medically accepted
             method of contraception. Patient's pregnancy confirmed by positive pregnancy test, or
             breast-feeding.

         13. Expected life expectancy &lt; 1 year

         14. Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests which, in the judgment of the investigator, would
             preclude safe completion of the study.

         15. Unwillingness or inability to comply with the procedures described in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol Whan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheol Whan Lee, MD, PhD</last_name>
    <phone>82230103150</phone>
    <email>cheolwlee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Lifestyle modification</keyword>
  <keyword>Myocardial perfusion reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

